Page 27 - Read Online

Fabbrizi et al. Cancer Drug Resist 2020;3:775-90 I http://dx.doi.org/10.20517/cdr.2020.49 Page 789

71. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72.
72. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.
Semin Radiat Oncol 2009;19:63-8.
73. Byeon HK, Ku M, Yang J. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp
Mol Med 2019;51:1-14.
74. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and
neck. N Engl J Med 2006;354:567-78.
75. Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, et al. Concurrent cetuximab versus platinum-based chemoradiation for the definitive
treatment of locoregionally advanced head and neck cancer. Head Neck 2015;37:386-92.
76. Stegeman H, Span PN, Cockx SC, Peters JP, Rijken PF, et al. EGFR-inhibition enhances apoptosis in irradiated human head and neck
xenograft tumors independent of effects on DNA repair. Radiat Res 2013;180:414-21.
77. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-
positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019;393:40-50.
78. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-
positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393:51-60.
79. Rieckmann T, Kriegs M. The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: a radiobiologists perspective.
Clin Transl Radiat Oncol 2019;17:47-50.
80. Martinez-Useros J, Garcia-Foncillas J. The challenge of blocking a wider family members of EGFR against head and neck squamous cell
carcinomas. Oral Oncol 2015;51:423-30.
81. Gurtner K, Deuse Y, Butof R, Schaal K, Eicheler W, et al. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies
or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 2011;99:323-30.
82. Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, et al. Radiosensitization of HNSCC cells by EGFR inhibition depends on the
induction of cell cycle arrests. Oncotarget 2016;7:45122-33.
83. Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, et al. Afatinib vs Placebo as adjuvant therapy after chemoradiotherapy in squamous cell
carcinoma of the head and neck: a randomized clinical trial. JAMA Oncol 2019;5:1170-80.
84. Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, et al. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent
or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an
open-label, randomised phase III trial. Ann Oncol 2019;30:1831-9.
85. Khaznadar SS, Khan M, Schmid E, Gebhart S, Becker ET, et al. EGFR overexpression is not common in patients with head and neck
cancer. Cell lines are not representative for the clinical situation in this indication. Oncotarget 2018;9:28965-75.
86. Kriegs M, Clauditz TS, Hoffer K, Bartels J, Buhs S, et al. Analyzing expression and phosphorylation of the EGF receptor in HNSCC. Sci
Rep 2019;9:13564.
87. Curtis KK, Wong WW, Ross HJ. Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the
head and neck. Crit Rev Oncol Hematol 2016;103:86-98.
88. Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy
plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-76.
89. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, et al. A randomized double-blind phase III study of nimorazole as a
hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck
Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46.
90. Toustrup K, Sorensen BS, Lassen P, Wiuf C, Alsner J, et al. Gene expression classifier predicts for hypoxic modification of radiotherapy
with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012;102:122-9.
91. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, et al. HPV-associated p16-expression and response to hypoxic modification
of radiotherapy in head and neck cancer. Radiother Oncol 2010;94:30-5.
92. NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally
Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) NIMRAD. The
Christie NHS Foundation Trust; 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT01950689. [Last accessed on 9 Sep 2020]
93. Bonnet M, Hong CR, Wong WW, Liew LP, Shome A, et al. Next-generation hypoxic cell radiosensitizers: nitroimidazole
alkylsulfonamides. J Med Chem 2018;61:1241-54.
94. McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer
2010;116:1859-71.
95. Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, et al. Activity of the vascular-disrupting agent
5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia 2006;8:534-42.
96. Wilson WR, Li AE, Cowan DS, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-
acetic acid. Int J Radiat Oncol Biol Phys 1998;42:905-8.
97. Parsons JL, Dianov GL. Co-ordination of base excision repair and genome stability. DNA Repair (Amst) 2013;12:326-33.
98. Dianov GL, Parsons JL. Co-ordination of DNA single strand break repair. DNA Repair (Amst) 2007;6:454-60.
99. Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol
2017;18:610-21.
100. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic
strategy. Nature 2005;434:917-21.